2) More robust Type-I associated T and B cell responses can be measured after intravenous administration, 3) intravenous administration of PLGA nanovaccines is safe and do not cause any toxicity up to 50 mg/kg dose, 4) intravenously applied iNKT cell-activating nanovaccines can synergize with immune checkpoint modulation, PD-1 blockade and 4-1BB stimulation, in controlling tumor growth. Here, TNFRSF9 is linked to neoplasm.